Tumeurs solides

TITRE	(EN) A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
PROTOCOLE ID	GO43860
CLINICAL TRIAL.gov ID	NCT05581004
TYPE(S) DE CANCER	Tumeurs solides
PHASE	Phase I
TYPE D'ÉTUDE	Clinique
INSTITUTION	HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS 3755 rue de la Côte Ste. Catherine (514) 340-8222
VILLE	Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E)	Wilson Miller
COORDONATEUR(RICE)	Ding Yuan Guo ding.yuan.guo.ccomtl@ssss.gouv.qc.ca 514-340-8222 poste 24599
STATUT	Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ	(EN) Life expectancy at least 12 weeks Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Measurable disease according to Response Evaluation criteria in Solid Tumors (RECIST) Version 1.1 Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy Tumor Specimen availability
CRITÈRES D'EXCLUSION	(EN) Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of study treatment Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment Active hepatitis B or C or tuberculosis Positive test for human immunodeficiency virus (HIV) infection Acute or chronic active Epstein-Barr virus (EBV) infection at screening Administration of a live, attenuated vaccine (e.g., FluMist) within 4 weeks before first RO7502175 infusion Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases Active or history of autoimmune disease Prior allogeneic stem cell or organ transplantation